Research programme: hearing disorder therapies - AudioCure Pharma

Drug Profile

Research programme: hearing disorder therapies - AudioCure Pharma

Alternative Names: AC-002; AC-102; AC-103; AC-104

Latest Information Update: 17 Jan 2014

Price : $50

At a glance

  • Originator AudioCure Pharma
  • Class Small molecules
  • Mechanism of Action Adenosine triphosphatase stimulants; Antioxidants; Apoptosis inhibitors; Brain-derived neurotrophic factor expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hearing disorders

Most Recent Events

  • 17 Jan 2014 Preclinical trials in Hearing disorders in Germany (Intratympanic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top